freshpet - FRPT
FRPT
Close Chg Chg %
62.18 -0.19 -0.31%
Closed Market
61.99
-0.19 (0.31%)
Volume: 1.09M
Last Updated:
Dec 4, 2025, 4:00 PM EDT
Company Overview: freshpet - FRPT
FRPT Key Data
| Open $62.53 | Day Range 61.04 - 63.11 |
| 52 Week Range 46.76 - 164.00 | Market Cap $3.03B |
| Shares Outstanding 48.81M | Public Float 48.05M |
| Beta 1.72 | Rev. Per Employee N/A |
| P/E Ratio 25.47 | EPS $2.53 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.07M |
FRPT Performance
| 1 Week | 8.45% | ||
| 1 Month | 12.22% | ||
| 3 Months | 12.16% | ||
| 1 Year | -59.84% | ||
| 5 Years | -54.07% |
FRPT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
About freshpet - FRPT
Freshpet, Inc. engages in the manufacturing, marketing, and distribution of pet food and pet treats for dogs and cats. Its products are blends of fresh meats, vegetables, and fruits farmed locally and made at Freshpet kitchens. Its products include Deli Fresh Grain Free Chicken Recipe for Dogs, Joy Turkey and Apple Bites Treats, Nature's Fresh Grain Free Chicken Recipe for Cats, and Vital Grain Free Chicken and Ocean Whitefish Recipe for Cats. The company was founded by Scott Morris and Cathal Walsh in November 2004 and is headquartered in Bedminster, NJ.
FRPT At a Glance
Freshpet, Inc.
1450 US-206
Bedminster, New Jersey 07921
| Phone | 1-201-520-4000 | Revenue | 975.18M | |
| Industry | Food: Specialty/Candy | Net Income | 46.93M | |
| Sector | Consumer Non-Durables | 2024 Sales Growth | 27.159% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,296 | |
| View SEC Filings |
FRPT Valuation
| P/E Current | 25.467 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 158.627 |
| Price to Sales Ratio | 7.633 |
| Price to Book Ratio | 6.835 |
| Price to Cash Flow Ratio | 48.24 |
| Enterprise Value to EBITDA | 67.724 |
| Enterprise Value to Sales | 7.792 |
| Total Debt to Enterprise Value | 0.056 |
FRPT Efficiency
| Revenue/Employee | 752,451.389 |
| Income Per Employee | 36,207.562 |
| Receivables Turnover | 14.253 |
| Total Asset Turnover | 0.642 |
FRPT Liquidity
| Current Ratio | 4.42 |
| Quick Ratio | 3.603 |
| Cash Ratio | 2.717 |
FRPT Profitability
| Gross Margin | 38.36 |
| Operating Margin | 3.957 |
| Pretax Margin | 4.873 |
| Net Margin | 4.812 |
| Return on Assets | 3.088 |
| Return on Equity | 4.672 |
| Return on Total Capital | 3.172 |
| Return on Invested Capital | 3.292 |
FRPT Capital Structure
| Total Debt to Total Equity | 40.184 |
| Total Debt to Total Capital | 28.665 |
| Total Debt to Total Assets | 26.928 |
| Long-Term Debt to Equity | 39.858 |
| Long-Term Debt to Total Capital | 28.433 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Freshpet - FRPT
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 425.49M | 595.34M | 766.89M | 975.18M | |
Sales Growth
| +33.47% | +39.92% | +28.82% | +27.16% | |
Cost of Goods Sold (COGS) incl D&A
| 275.51M | 423.09M | 531.87M | 601.10M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 31.80M | 35.93M | 58.52M | 73.61M | |
Depreciation
| 30.80M | 35.70M | 58.17M | 73.61M | |
Amortization of Intangibles
| - | 1.00M | 223.00K | 348.00K | |
COGS Growth
| +42.08% | +53.57% | +25.71% | +13.02% | |
Gross Income
| 149.98M | 172.25M | 235.02M | 374.08M | |
Gross Income Growth
| +20.09% | +14.85% | +36.44% | +59.17% | |
Gross Profit Margin
| +35.25% | +28.93% | +30.65% | +38.36% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 171.88M | 223.10M | 264.76M | 335.49M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 171.88M | 223.10M | 264.76M | 335.49M | |
SGA Growth
| +41.79% | +29.80% | +18.67% | +26.71% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 1.76M | 734.00K | (67.00K) | |
EBIT after Unusual Expense
| (23.66M) | (51.59M) | (29.67M) | 38.59M | |
Non Operating Income/Expense
| (987.00K) | 1.31M | 12.26M | 21.20M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | 9.92M | - |
Interest Expense
| 2.88M | 5.21M | 14.10M | 12.26M | |
Interest Expense Growth
| +137.79% | +80.71% | +170.68% | -13.02% | |
Gross Interest Expense
| 2.88M | 5.21M | 14.10M | 12.26M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (27.53M) | (55.48M) | (31.51M) | 47.52M | |
Pretax Income Growth
| -781.59% | -101.51% | +43.20% | +250.80% | |
Pretax Margin
| -6.47% | -9.32% | -4.11% | +4.87% | |
Income Tax
| 162.00K | 282.00K | 210.00K | 598.00K | |
Income Tax - Current - Domestic
| 162.00K | 282.00K | 210.00K | 598.00K | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | 9.92M | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (29.70M) | (59.49M) | (33.61M) | 46.92M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (29.70M) | (59.49M) | (33.61M) | 46.92M | |
Net Income Growth
| -831.59% | -100.32% | +43.50% | +239.60% | |
Net Margin Growth
| -6.98% | -9.99% | -4.38% | +4.81% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (29.70M) | (59.49M) | (33.61M) | 46.92M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (29.70M) | (59.49M) | (33.61M) | 46.92M | |
EPS (Basic)
| -0.6918 | -1.288 | -0.6979 | 0.9678 | |
EPS (Basic) Growth
| -762.59% | -86.18% | +45.82% | +238.67% | |
Basic Shares Outstanding
| 42.93M | 46.19M | 48.16M | 48.49M | |
EPS (Diluted)
| -0.6918 | -1.288 | -0.6979 | 0.9337 | |
EPS (Diluted) Growth
| -762.59% | -86.18% | +45.82% | +233.79% | |
Diluted Shares Outstanding
| 42.93M | 46.19M | 48.16M | 50.26M | |
EBITDA
| 9.89M | (14.93M) | 28.78M | 112.20M | |
EBITDA Growth
| -60.09% | -250.89% | +292.80% | +289.89% | |
EBITDA Margin
| +2.32% | -2.51% | +3.75% | +11.51% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 67.20 | |
| Number of Ratings | 17 | Current Quarters Estimate | 0.409 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 2.493 | |
| Last Quarter’s Earnings | 1.86 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.93 | Next Fiscal Year Estimate | 1.467 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 7 | 10 | 10 |
| Mean Estimate | 0.41 | 0.17 | 2.49 | 1.47 |
| High Estimates | 0.67 | 0.35 | 2.91 | 2.41 |
| Low Estimate | 0.26 | 0.07 | 2.14 | 0.90 |
| Coefficient of Variance | 31.33 | 55.04 | 10.64 | 35.19 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 10 | 13 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 6 | 6 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Freshpet - FRPT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Freshpet - FRPT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 14, 2025 | Jacki S. Kelley Director | 11,093 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Nishu Patel Chief Accounting Officer | 3,240 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Thembeka Machaba Chief Human Resources Officer | 8,870 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Lauri Kien Kotcher Director | 2,478 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Todd E. Cunfer Chief Financial Officer | 38,563 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Leta DeDe Priest Director | 12,167 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Olu Fajemirokun-Beck Director | 9,237 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | David B. Biegger Director | 5,899 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Cathal Walsh SVP-Managing Director, Europe | 7,574 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Scott Morris President & Co-Founder | 141,430 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Craig D. Steeneck Director | 33,911 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | David J. West Director | 4,364 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | William B. Cyr Chief Executive Officer; Director | 87,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Nicki Baty Chief Operating Officer | 21,230 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Lisa Alexander GC & Corp. Sec. | 2,904 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Timothy R. McLevish Director | 30,040 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Joseph E. Scalzo Director | 4,040 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Daryl G. Brewster Director | 57,529 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Timothy R. McLevish Director | 27,608 | Open market or private purchase of non-derivative security Non-derivative transaction at $103.55 per share | 2,858,808.40 |
| Feb 27, 2025 | Timothy R. McLevish Director | 27,358 | Open market or private purchase of non-derivative security Non-derivative transaction at $102.5 per share | 2,804,195.00 |